Drug Treatment for Pathological Gambling
Information source: National Institute of Mental Health (NIMH)
Information obtained from ClinicalTrials.gov on May 08, 2007
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Gambling
Intervention: Bupropion (Drug)
Phase: N/A
Status: No longer recruiting
Sponsored by: National Institute of Mental Health (NIMH)
Summary
This study will determine whether the drug bupropion is an effective treatment for Pathological Gambling.
Clinical Details
Official title:
Bupropion Versus Placebo in the Treatment of Pathological Gambling
Study design: Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Detailed description:
As gambling opportunities proliferate, PG has become a major health concern. Despite its importance, few treatment options with proven efficacy exist. This study will attempt to identify an effective treatment for PG.
Participants are randomly assigned to receive either bupropion or placebo for 12 weeks. Participants are assessed at baseline and at Weeks 2, 3, 4, 5, 6, 8, 10, and 12. Self administered questionnaires and interviews are used to assess participants. Follow-up assessments are made 1, 3, and 6 months after study completion.
Eligibility
Minimum age: 18 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- PG for at least 1 year
Locations and Contacts
Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, Iowa 52242, United States
Additional Information
Starting date:
July 2002
Last updated: July 28, 2006
|
